ABEO — ABEONA THERAPEUTICS INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 318306 ·
Last close
$5.49
Market Cap
$312.90M
52W High
$6.07
52W Low
$4.23
ADV30
1,050,544
Next earnings
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 8,720,000 6,024,000 -23,033,000 -17,075,000 198,494,000 61,374,000 53,555,000
Dec 2025 5,420,000 2,583,000 -22,911,000 -20,460,000 219,570,000 78,437,000 60,354,000
Sep 2025 0 -488,000 -24,018,000 -5,161,000 231,095,000 82,884,000 59,862,000
Jun 2025 400,000 300,000 -22,792,000 108,833,000 246,233,000 163,535,000 82,657,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-76,326,000
Investing CF
$105,028,000
Financing CF
$26,040,000
CapEx
$-7,975,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.74
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-742,075,000
Inventory
$5,493,000
Receivables
$6,715,000
ST Investments
$112,967,000
EBIT TTM
$75,023,000
Pretax Income TTM
$71,283,000
Interest Exp TTM
$3,740,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$14,540,000
EBITDA
$-90,049,000
Free Cash Flow
$-56,589,752
Enterprise Value
$164,955,584
Total Cash
$168,271,008
Total Debt
$23,173,000
Shares Out
56,995,144
Trailing EPS
$0.95
Book Value
$2.55
ROE
71.0%
ROA
-38.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 5,820,000 -89,448,000 71,183,000 219,570,000 60,354,000 -76,326,000
Dec 2024 0 -64,211,000 -63,734,000 108,931,000 64,900,000 -56,015,000
Dec 2023 3,500,000 -48,200,000 -54,188,000 64,002,000 49,176,000 -37,009,000
Dec 2022 1,414,000 -45,257,000 -39,696,000 64,214,000 37,453,000 -43,483,000

TTM Snapshot

Revenues TTM
$2,309,000
NetIncome TTM
$-15,533,000
OpCashFlow TTM
$0
Assets (Latest)
$16,582,000
Forward EPS
$0.29

Peers — same industry

TickerNameMarket CapLastDaily %
SLN Silence Therapeutics plc $313.64M $6.64
RZLT Rezolute, Inc. $317.76M $3.30
TENX TENAX THERAPEUTICS, INC. $317.77M $11.98
ELDN Eledon Pharmaceuticals, Inc. $300.26M $3.89
AMRN AMARIN CORP PLC\UK $299.86M $14.30

News headlines (Yahoo Finance, 1h cache)

Spotlight On 3 Growth Companies With Strong Insider Stakes
2026-05-26 17:36 · Yahoo
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
2026-05-26 12:30 · Yahoo
3 Promising Growth Companies With Insider Ownership Up To 27%
2026-05-26 11:36 · Yahoo
Top Growth Companies With Strong Insider Stakes May 2026
2026-05-25 11:35 · Yahoo
May 2026's Top Insider-Owned Growth Companies
2026-05-22 17:36 · Yahoo
3 Growth Companies With High Insider Ownership And 15% Revenue Growth
2026-05-22 11:35 · Yahoo
ABEO: Three Patients Treated in 1Q26 with Two Additional QTCs Activated
2026-05-18 13:05 · Yahoo
Abeona Therapeutics Inc (ABEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
2026-05-13 23:01 · Yahoo
Abeona Therapeutics Q1 Earnings Call Highlights
2026-05-13 14:07 · Yahoo
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
2026-05-13 13:51 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.